Mitozolomide controlled-release planting dose for treating entity tumor

Disclosed is a mitoxatrone diamox sustained release implant for treating solid tumor, which is characterized in that the sustained release implant contains anticancer effective amount of mitoxatrone diamox, sustained release excipient and a certain of sustained release regulator. The solid tumor comprises pancreatic cancer, lung cancer, liver cancer, breast cancer, brain tumor, ovarian cancer, prostate cancer, esophagus cancer, lymphoma, osteosarcoma and colorectal cancer. The sustained release excipient is mainly one or the combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly( L-lactide-co-ethyl phosphate) and poly( L-lactide-co-phosphoric propyl). In the processes of degradation and absorption, the sustained release implant can slowly release the mitoxatrone diamox on part of the tumor, so the sustained release implant obviously lowers systemic toxicity of the mitoxatrone diamox and can keep effective drug concentration on part of the tumor. If the sustained release implant i